Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Capital Expenditures (2016 - 2019)

Historic Capital Expenditures for Soleno Therapeutics (SLNO) over the last 6 years, with Q4 2019 value amounting to $5000.0.

  • Soleno Therapeutics' Capital Expenditures rose 15000.0% to $5000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $21000.0, marking a year-over-year decrease of 9636.05%. This contributed to the annual value of $218000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Soleno Therapeutics reported Capital Expenditures of $5000.0 as of Q4 2019, which was up 15000.0% from $6000.0 recorded in Q2 2019.
  • In the past 5 years, Soleno Therapeutics' Capital Expenditures registered a high of $570000.0 during Q3 2017, and its lowest value of -$244223.0 during Q4 2015.
  • Over the past 5 years, Soleno Therapeutics' median Capital Expenditures value was $3000.0 (recorded in 2016), while the average stood at $41973.2.
  • Examining YoY changes over the last 5 years, Soleno Therapeutics' Capital Expenditures showed a top increase of 2840000.0% in 2017 and a maximum decrease of 20000.0% in 2017.
  • Soleno Therapeutics' Capital Expenditures (Quarter) stood at -$244223.0 in 2015, then soared by 97.05% to -$7205.0 in 2016, then skyrocketed by 8011.17% to $570000.0 in 2017, then tumbled by 99.65% to $2000.0 in 2018, then skyrocketed by 150.0% to $5000.0 in 2019.
  • Its Capital Expenditures stands at $5000.0 for Q4 2019, versus $6000.0 for Q2 2019 and $10000.0 for Q1 2019.